Human rotavirus G9P[6] strain and use as a vaccine
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsBaoming Jiang, Yuhuan Wang
Life of this patent
Estimating the term…
Abstract
Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy.
Claims19
An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:
- 6.
A pharmaceutical composition comprising an effective amount of an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:
- 6, a nucleic acid molecule encoding the polypeptide, or a vector comprising the nucleic acid molecule, and a pharmaceutically acceptable carrier, and further comprising an inactivated G1P[8] rotavirus.
A method of inducing an immune response to a rotavirus protein in a subject, comprising:
- administering an effective amount of a pharmaceutical composition comprising an effective amount of an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:
- 6, a nucleic acid molecule encoding the polypeptide, or a vector comprising the nucleic acid molecule, and a pharmaceutically acceptable carrier, and an adjuvant to the subject,
- thereby inducing the immune response to the rotavirus protein in the subject.
Dependencies are inferred from the claim text.